PRIMARY OBJECTIVE:
I. Tolerability.
SECONDARY OBJECTIVES:
I. Tolerability in prespecified subpopulations.
II. Prostate-specific antigen (PSA) response at 7 months.
OUTLINE: Patients are assigned to 1 of 2 arms per treating physician preference.
ARM I: Patients receive abiraterone and prednisone per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.
ARM II: Patients receive darolutamide per SOC. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples during screening and on study.
After completion of study intervention, patients are followed up for a total of 3 years.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Ability to understand and willingness to sign an informed consent form
Histologically confirmed prostate adenocarcinoma
Advanced prostate cancer appropriate for treatment with abiraterone acetate plus prednisone or darolutamide as assessed by the treating physician
Participants are encouraged to be currently treated with androgen deprivation therapy (ADT) or having undergone bilateral orchiectomy
Performance status 0 - 2 (Karnofsky ≥ 50%)
Age ≥ 18 years at time of consent
Life expectancy ≥ 6 months per investigator discretion
Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study
You may not be if
Have been on either abiraterone or darolutamide for \> 28 days prior to initiating enrollment
Any condition that in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial
Clareo Health | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
